Niklas Mattsson

Niklas Mattsson

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Niklas Mattsson

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2015 in JAMA
Verified
Journal Article
Open access
PDF file
WJWillemijn J. Jansen
Willemijn J. Jansen
RORik Ossenkoppele
Rik Ossenkoppele
DKDirk L. Knol
Dirk L. Knol
BTBetty Tijms
Betty Tijms
PSPhilip Scheltens
Philip Scheltens
HZHenrik Zetterberg
Henrik Zetterberg
Alzheimer disease (AD) is the most common cause of dementia, with a worldwide prevalence of about 25 million in 2010, expected to be doubled by 2030 because of increased life expectancy.1 The earliest recognizable pathological event in AD is cerebral amyloid-β aggregation.2 This pathology may be present up to 20 years before the onset of dementia.3,4 Novel research criteria for AD in individuals without dementia emphasize the presence of amyloid pathology to define the first stage of the disease.5,6

1 May 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
NMNiklas Mattsson
Niklas Mattsson
UAUlf Andreasson
Ulf Andreasson
HZHenrik Zetterberg
Henrik Zetterberg
KBKaj Blennow
Kaj Blennow
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
Alzheimer disease (AD) is a neurodegenerative disease that is characterized by brain accumulation of β-amyloid (Aβ) and tau, progressive atrophy, and cognitive decline. Biomarkers that capture biological processes in AD are increasingly used to support the diagnosis of AD in research, drug development, and clinical practice.1 The most well-established AD biomarkers include structural magnetic resonance imaging (MRI); cerebrospinal fluid (CSF) biomarkers of Aβ, tau, and neuronal injury; and positron emission tomographic imaging of Aβ, tau, and brain metabolism.2-4 Use of these biomarkers is hampered by a high degree of invasiveness, high costs, or limited availability.5 Blood-based biomarkers for AD may allow for efficient monitoring of disease processes in AD and could be used as a screening tool in primary care. One potential blood-based biomarker for AD is the neuronal injury marker neurofilament light (NFL)6 because patients with AD have increased CSF concentrations of NFL.7 Results from some studies8,9 suggest that patients with AD have increased plasma NFL concentrations. However, those studies were performed using standard immunoassay techniques with suboptimal analytical sensitivity to accurately quantify low abundant brain-specific proteins in blood samples.10 For this reason, our group has recently transferred the CSF NFL assay to an ultrasensitive single-molecule array (Simoa; Quanterix Corporation) platform, which provides an analytical sensitivity of 0.6 pg/mL compared with 78.0 pg/mL for the corresponding enzyme-linked immunosorbent assay (ELISA).10 Plasma NFL concentrations can be measured in all samples using the ultrasensitive single-molecule array and correlate closely with the corresponding CSF concentrations.11,12 Herein, we test this novel plasma NFL assay in patients with AD for the first time, to our knowledge. We studied cognitively healthy control individuals, patients with mild cognitive impairment (MCI) (MCI group), and patients with AD dementia (AD group) in a large prospective study. We tested the hypotheses that the plasma NFL concentration is increased in AD and that it correlates with impaired cognition, neuroimaging abnormalities, and CSF biomarkers of AD pathologic features.

22 July 2009 in JAMA
Verified
Journal Article
Open access
PDF file
NMNiklas Mattsson
Niklas Mattsson
HZHenrik Zetterberg
Henrik Zetterberg
OHOskar Hansson
Oskar Hansson
NANiels Andreasen
Niels Andreasen
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
KBKaj Blennow
Kaj Blennow
ContextSmall single-center studies have shown that cerebrospinal fluid (CSF) biomarkers may be useful to identify incipient Alzheimer disease (AD) in patients w

31 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSebastian Palmqvist
Sebastian Palmqvist
MSMichael Schöll
Michael Schöll
OSOlof Strandberg
Olof Strandberg
NMNiklas Mattsson
Niklas Mattsson
ESErik Stomrud
Erik Stomrud
OHOskar Hansson
Oskar Hansson
It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with Alzheimer’s disease (AD). Recently, we showed that abnormal levels of Aβ42 in cerebrospinal fluid (CSF) can be detected before abnormal amyloid can be detected using PET in individuals with preclinical AD. Using these approaches, here we identify the earliest preclinical AD stage in subjects from the ADNI and BioFINDER cohorts. We show that Aβ accumulation preferentially starts in the precuneus, medial orbitofrontal, and posterior cingulate cortices, i.e., several of the core regions of the default mode network (DMN). This early pattern of Aβ accumulation is already evident in individuals with normal Aβ42 in the CSF and normal amyloid PET who subsequently convert to having abnormal CSF Aβ42. The earliest Aβ accumulation is further associated with hypoconnectivity within the DMN and between the DMN and the frontoparietal network, but not with brain atrophy or glucose hypometabolism. Our results suggest that Aβ fibrils start to accumulate predominantly within certain parts of the DMN in preclinical AD and already then affect brain connectivity.

1 September 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
CBClaire Bridel
Claire Bridel
WWWessel N. van Wieringen
Wessel N. van Wieringen
HZHenrik Zetterberg
Henrik Zetterberg
BTBetty M. Tijms
Betty M. Tijms
CTCharlotte E. Teunissen
Charlotte E. Teunissen
EWEdward Wild
Edward Wild
Identifying neuroaxonal damage and quantifying the intensity of this process is a critical step in patient care because it may support diagnosis and help estimate the prognosis of neurological conditions. In addition, it is essential for the evaluation of drug candidates with disease-modifying potential. Neurofilament light protein (NfL) is an abundant cytoskeletal protein exclusively expressed by central and peripheral neurons. Elevated levels of NfL in cerebrospinal fluid (CSF) were first reported in neurodegenerative conditions more than 20 years ago,1 sparking interest in the potential of this neuron-specific protein as a biomarker. Since then, elevated levels of NfL in CSF (cNfL) have been described in a number of neurological and psychiatric conditions. The magnitude of the increase in inflammatory, degenerative, infectious, ischemic, and traumatic neurological conditions, as well as in psychiatric disorders, varies between conditions and studies. To date, cNfL levels have not been compared systematically between neurological disorders, and patient numbers in individual studies are often low. A positive association between cNfL and age has been reported in healthy controls (HC)2 but was not systematically investigated in neurological conditions and may alter the performance of this biomarker across age categories. Together, these questions limit clinical implementation of cNfL. To compare cNfL levels between diagnoses, assess the association of age and sex with these variables, and evaluate the potential of cNfL level as a diagnostic biomarker, we performed a systematic review and meta-analysis on individual data collected from studies reporting cNfL levels in diseases and controls.

1 July 2019 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
NMNiklas Mattsson
Niklas Mattsson
NCNicholas C. Cullen
Nicholas C. Cullen
UAUlf Andreasson
Ulf Andreasson
HZHenrik Zetterberg
Henrik Zetterberg
KBKaj Blennow
Kaj Blennow
Importance Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. Objective To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD. Design, Setting, and Participants This North American cohort study used data from 1583 individuals in the multicenter Alzheimer’s Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018. Exposures Clinical diagnosis, Aβ and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose–positron emission tomography), and tests on cognitive scores. Main Outcomes and Measures The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with Aβ, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures. Results Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L;P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low Aβ42 [P = .001], high total tau [P = .02], and high phosphorylated tau levels [P = .02]), magnetic resonance imaging measures (small hippocampal volumes [P < .001], thin regional cortices [P = .009], and large ventricular volumes [P = .002]), low fluorodeoxyglucose–positron emission tomography uptake (P = .01), and poor cognitive performance (P < .001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A–T+N+ (P < .001), A+T–N+ (P < .001), and A+T+N+ (P < .001), and increased rates of NfL levels were seen in A–T+N– (P = .009), A–T+N+ (P = .02), A+T–N+ (P = .04), and A+T+N+ (P = .002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (allP < .05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia). Conclusions and Relevance The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.